HealthPolitics
STAT+: AbbVie wins FDA nod for Parkinson’s pill
Publication: STAT
Author: Meghana Keshavan
Source published: 28/09/2026, 13:40:32 UTC
Briefing created: 28/09/2026, 13:52:22 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/09/2026, 13:51:24 UTC.
Briefings
STAT+ reports that Kodiak Sciences achieved statistical equivalence to Eylea in a Phase 3 trial for Zenkuda, an experimental vision-sparing treatment for age-related blindness. The article also notes Merck's $400 million upfront payment to SciBrunch Therapeutics for a KRAS G12D-targeting cancer drug and Novo Nordisk's shift toward marketing GLP-1 drugs as weight loss products. Coverage is limited to the provided text, which lacks specific trial dates, patient numbers, or long-term outcome data.
Key points
- Kodiak Sciences achieved statistical equivalence to Eylea in a Phase 3 clinical trial for Zenkuda, an experimental vision-sparing treatment for age-related blindness.
- Merck paid $400 million upfront to SciBrunch Therapeutics for global license rights to a preclinical cancer drug targeting KRAS G12D mutations.
Context and limitations
This briefing covers only the specific trial results, licensing deal, and marketing shift mentioned in the source text. It does not include specific trial dates, patient counts, or long-term outcome data.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 28/09/2026, 13:52:22 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeib5hxhwcaausbjlg36qoyusshikxd2kh4r2tncqukqc3p6cmxniuq